Liat Hammer, MD
Sahezeel Awadia, PhD
Sahezeel Awadia received his PhD from the University of Toledo and joined the Rehemtulla laboratory in 2019. The Rehemtulla laboratory has identified FADD (Fas Associated Death Domain), a protein commonly associated with apoptotic cell death, as a key mediator of the G1 to S transition. Dr. Awadia's recent work has identified FADD as a requisite regulator of the APC/C complex, wherein it functions as an APC/C inhibitor during the G1 to S transition.
Long Jiang, PhD
Dr. Jiang received his PhD from the University of Science and Technology, China in 2017. He joined the Michael Green laboratory in 2019, and works on preclinical research examining novel determinants of immunotherapy and radiotherapy efficacy.
Navya Korimerla, PhD
Navya is a post-doctoral research fellow in the Wahl lab. Navya obtained masters and bachelor's in India, after which she earned her Ph.D. in Biomedical Engineering from Stony Brook University, NY. Her doctoral research was on understanding how kinase substrate specificity of EGFR and PDGFR diversifies IL6 signaling and pro-metastatic phenotypes. In the Wahl lab, her research focuses on targeting the metabolic vulnerabilities to radiosensitize MTAP-deleted GBMs. She also works on metabolic strategies to radiosensitize IDH1 wild-type GBMs. Outside of the lab she enjoys painting, learning music, movies, and traveling.
Albert Liang, PhD
Deanna Nellis, PhD
Andrew Scott, PhD
Dr. Scott is a cancer biologist interested in identifying and targeting metabolic vulnerabilities in tumors. He joined the team after completing his doctoral research studying how mitochondria regulate cell death and survival in cancer cells. In the Daniel Wahl and Lyssiotis labs, he is using in vivo models to determine how metabolic activity governs radiation resistance in brain tumors and targeting these pathways in patients.